Loading
Medpace Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 28 Feb 2025.
Medpace Holdings, Inc.: what insiders have been doing
This page follows insider dealings at Medpace Holdings, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Cincinnati, United States. The group dates from 1992. Between 18 October 2025 and 18 October 2026, 17 insiders published 84 filings.
There is no open-market purchase to report; the filings show 41 sales worth €296.2M by 8 insiders. At €31.2M, the sale published on 26 November 2025 by Troendle August J. is the largest of the period.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 84 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 12 purchases and 119 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.53 bn USD and net income at 451.1 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
312
Thresholds
n/a
Buy Volume
€81M
12 ops. · all time
Sell Volume
€723M
119 ops. · all time
Who traded when
BuySaleAugust J. Troendle35 sales
Susan E. Burwig6 sales
Cornelius P. McCarthy III3 sales
Ewald Stephen P1 buy2 sales
Brady Kevin M.1 sale
Brian T. Carley1 sale
+3 other insiders
Since the insiders bought
- +43.3%Entry US$319.17 · Close at T+365 US$457.47
- +65.7%Entry US$147.71 · Close at T+365 US$244.70
- +68.3%Entry US$145.38 · Close at T+365 US$244.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Medpace Holdings, Inc. Hold (neutral), based on 13 analysts. Average price target: US$595.92.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,181 of 24,148 companies
59.5
score / 100
Value40
Quality79
FCF yld3.9%
Earn yld2.6%
EV/EBITDA30.9x
ROE162%
Gross mgn30%
Net mgn18%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$609.89
Analyst consensus
13 analystsHold
US$370.00Target US$595.92(-2%)US$700.00
Income statement
RevenueUS$2.5B
Gross profitUS$760.6M30% margin
EBITDAUS$563.1M22% margin
Net incomeUS$451.1M17.7% margin
Valuation
PER (trailing)35.8x
PER (forward)31.6x
P/Book39.2x
Beta1.18
Balance sheet & cash
Market capUS$17B
Total debtUS$113.6M
Free Cash FlowUS$681.9M
Debt / Equity33%
Profitability & ownership
ROE162.2%
ROA20.1%
% insiders18.8%
% institutions90.8%
Last declaration on 14 October 2026
Declarations312 total
3,000 shares@ US$166.730.0029% mcap0.8% of flowCommon StockSEC:0001677418-26-000014:0
2,000 shares@ US$166.730.0020% mcap0.5% of flowCommon StockSEC:0001677418-26-000012:0
28 sharesCommon StockSEC:0001750355-26-000014:0
32 sharesCommon StockSEC:0001558592-26-000014:0
36 sharesCommon StockSEC:0001677791-26-000012:0
26,701 shares@ US$621.020.096% mcap2.0% of flowCommon StockSEC:0001622058-26-000022:0
21,966 shares@ US$625.470.079% mcap1.6% of flowCommon StockSEC:0001622058-26-000022:1
154 shares@ US$620.600.0006% mcap0.0% of flowCommon StockSEC:0001622058-26-000020:0
2,410 shares@ US$620.070.0087% mcap0.2% of flowCommon StockSEC:0001622058-26-000020:1
16,083 shares@ US$628.640.058% mcap1.2% of flowCommon StockSEC:0001622058-26-000018:0
27,833 shares@ US$621.330.10% mcap2.1% of flowCommon StockSEC:0001622058-26-000018:1
21,883 shares@ US$623.290.078% mcap1.7% of flowCommon StockSEC:0001622058-26-000016:0
49,018 shares@ US$628.110.18% mcap3.8% of flowCommon StockSEC:0001622058-26-000016:1
10,880 shares@ US$620.400.039% mcap0.8% of flowCommon StockSEC:0001622058-26-000014:0
3,000 shares@ US$166.730.0029% mcap0.7% of flowCommon StockSEC:0001677418-26-000010:0
15,971 shares@ US$620.840.057% mcap1.2% of flowCommon StockSEC:0001622058-26-000012:0
8,770 shares@ US$621.290.031% mcap0.7% of flowCommon StockSEC:0001622058-26-000012:1
650 shares@ US$620.270.0023% mcap0.0% of flowCommon StockSEC:0001622058-26-000010:0
3,858 shares@ US$617.810.013% mcap37.9% of flowCommon StockSEC:0001558592-26-000010:1
3,858 shares@ US$84.360.0018% mcap5.2% of flowCommon StockSEC:0001558592-26-000010:0
673 shares@ US$620.380.0024% mcap0.1% of flowCommon StockSEC:0001622058-26-000008:0
4,000 shares@ US$620.030.014% mcap0.3% of flowCommon StockSEC:0001622058-26-000008:1
3,858 shares@ US$617.8130.013% mcap37.9% of flowCommonSEC144:0001959173-26-006461
13,995 shares@ US$624.450.049% mcap1.0% of flowCommon StockSEC:0000892251-26-000152:0
1,983 shares@ US$620.230.0069% mcap0.1% of flowCommon StockSEC:0000892251-26-000152:1
25 of 312 declarations
About Medpace Holdings, Inc.
Medpace Holdings, Inc. (ticker: MEDP) is a U.S.-listed company trading on the NASDAQ in the United States. For equity investors, Medpace is best understood as a high-science healthcare services business rather than a drug developer: it is a full-service clinical contract research organization (CRO) that supports biotechnology, pharmaceutical, and medical device sponsors across the full clinical development cycle, from Phase I through Phase IV. Its integrated model spans clinical operations, project management, regulatory consulting, data management, biostatistics, central laboratory services, imaging, bioanalytical testing, and cardiac safety capabilities. ([investor.medpace.com](https://investor.medpace.com/?utm_source=openai))
The company was founded in 1992 in Cincinnati, Ohio, by Dr. August J. Troendle, who remains CEO and Chairman. Medpace’s global headquarters is still based in Cincinnati, United States, where the company has built a large clinical research campus and key shared-service infrastructure. Over time, Medpace has expanded well beyond its U.S. base into Europe, Asia-Pacific, Latin America, and other regions, with office and laboratory locations across six continents. That geographic footprint is strategically important in modern clinical development, where sponsors need access to patients, local regulatory knowledge, and cross-border execution capabilities. ([medpace.com](https://www.medpace.com/careers/about-medpace/?utm_source=openai))
Read moreShow less
Medpace’s competitive positioning is centered on a disciplined, single-vendor, full-service operating model. The company emphasizes scientific depth and therapeutic specialization, aiming to simplify outsourcing for clients that want one coordinated partner rather than a fragmented vendor network. Its owned laboratory and early-phase assets are a key differentiator: Medpace highlights wholly owned central labs, a bioanalytical lab, an imaging core lab, an ECG core lab, and a Phase I Unit in Cincinnati. The company also markets capabilities across several important therapeutic areas, including oncology, cardiology, metabolic disease, endocrine disorders, central nervous system conditions, antiviral and anti-infective programs, and newer crossover areas such as cell and gene therapy. ([medpace.com](https://www.medpace.com/?utm_source=openai))
From a market perspective, Medpace operates in a highly competitive global CRO industry, where scale, regulatory expertise, patient access, and operational consistency are critical. Its niche is not “lowest-cost outsourcing”; rather, Medpace is positioned as a scientifically driven partner for complex trials, especially for biotech clients that value speed, quality, and close study oversight. This positioning can support pricing power and margin resilience when execution is strong, although the business remains exposed to sponsor funding cycles and trial start timing. ([medpace.com](https://www.medpace.com/?utm_source=openai))
Recent developments underscore the company’s momentum. In the first quarter of 2026, Medpace reported revenue of $706.6 million, up 26.5% year over year, with net new business awards of $618.4 million and backlog of $2.93 billion at March 31, 2026. Management also reaffirmed full-year 2026 revenue guidance of $2.755 billion to $2.855 billion. In addition, the company disclosed that President Jesse Geiger intends to retire effective May 31, 2026, with CEO August Troendle temporarily reassuming the president role. For investors, Medpace currently combines strong operating execution, a sizeable backlog, and a clearly defined niche in the NASDAQ-listed U.S. healthcare services universe. ([investor.medpace.com](https://investor.medpace.com/news-releases/news-release-details/medpace-holdings-inc-reports-first-quarter-2026-results/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
